To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
2C-T-7 is a hallucinogenic phenethylamine of the 2C family. In his book PIHKAL (Phenethylamines I Have Known and Loved), Shulgin lists the dosage range as 10 to 30 mg. 2C-T-7 is generally taken orally, and produces psychedelic and entheogenic effects that last 8 to 15 hours. Up until a crackdown on sales after multiple reported deaths, 2C-T-7 was sold commercially in Dutch smartshops and online as "Blue Mystic". Other names that were sometimes used include Nexus, Lucky 7, 7 up, 7th heaven, Beautiful, and Tripstasy.
There has been little real research done on this chemical other than Shulgin's comments in PiHKAL. There have been a few small animal studies mostly aimed at detecting metabolites, and an informal amateur research paper written by an interested party called "Sulfurous Samadhi."
The mechanism that produces the hallucinogenic and entheogenic effects of 2C-T-7 is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines.
2C-T-7 also has a separate action as a selective monoamine oxidase A inhibitor. This makes 2C-T-7 a potentially dangerous drug as at high doses it can slow down the degradation of serotonin in the brain, which can lead to serotonin syndrome and potential death without treatment.
Several of the deaths involving 2C-T-7 followed co-administration of the drug with stimulants such as MDMA and ephedrine, so these kind of combinations should be avoided.
2C-T-7 is hallucinogenic. In PiHKAL, Shulgin writes that the hallucinations are unique. He also comments on the tenseness of his muscles and his change in voice tone, which lasted some days. Erowid gives the following effects list:
The drug can be taken orally or snorted, although nasal administration is extremely painful. Use of 2C-T-7 as a nootropic at low doses of 1-10mg has been reported, and it may be useful for this purpose in a similar manner to LSD, which shows modest stimulant and nootropic effects at doses of 10 µg.
The Partnership for a Drug-Free America reports that 2C-T-7 can be lethal even in small doses,. However, there have been at least three reported deaths related to 2C-T-7 use, mainly at doses of 30mg or more or combined with stimulants such as MDMA, as well as a number of very bad trips and hospitalizations, these mostly followed insufflation of 2C-T-7. In January of 2002, Rolling Stone published an article about 2C-T-7 entitled "The New (legal) Killer Drug", although the legal status of the drug was misrepresented in the article. It can cause nausea and, as with many other drugs, may be dangerous when combined with alcohol and/or stimulants.
Around the year 2000, 2C-T-7 began to change from an obscure chemical to a drug used at parties and clubs in North America and Europe as it became available through a number of grey-market commercial vendors. This aroused the attention of the authorities, and since many countries have scheduled the chemical.
The Netherlands was the first country in the world to ban 2C-T-7, after being sold in smartshops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market, but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.
2C-T-2 became commercially available in Sweden in the summer of 1998, being sold in smartshops similar to those in the Netherlands. On April 1, 1999, both 2C-T-2 and 2C-T-7, along with MBDB, BDB, 2C-B and PMMA, were banned in Sweden. This was not done by appending these drugs to the country's normal drug laws, but by passing a new law, "Förordning (1999:58) om förbud mot vissa hälsofarliga varor," which banned the drugs as being materials dangerous to health.
In 1999, Alexander Shulgin was sent a copy of a letter from the British Home Office to several of its administrative associates which in effect placed all compounds listed in PiHKAL into Class A, Britain's equivalent of Schedule I.
On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a Final Rule in the Federal Register permanently placing 2C-T-7 in Schedule I. (69 FR 12794).
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "2C-T-7". A list of authors is available in Wikipedia.|